🟢 Lantern Pharma is trading 9.5% up in pre-market amid biotech-sector strength

Lantern Pharma is trading 9.54% higher pre-market at $0.75, with biotech-sector strength possibly supporting shares; no direct catalyst is confirmed.

• Shares are compared with the previous close of $0.68 on October 22.
• Biotech ETF XBI is up 3.64% pre-market, which may be supporting shares.
• No new company-specific announcement explaining the move was identified. U.S. futures are lower amid weaker risk sentiment, so a broad-market explanation is unclear.